Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Masimo MASI recently announced that a U.S. court has found Politan Capital and its managing partner, Quentin Koffey, guilty of violating a sealing order by releasing information from ongoing court proceedings in a press release dated Sept. 12.
This incident is likely to become a critical factor in the lead-up to Masimo’s 2024 Annual Meeting on Sept. 19, where Politan aims to replace several board members, potentially leading to the ousting of the company’s long-standing CEO and founder, Joe Kiani. The ruling has raised significant issues concerning corporate governance and the ethical conduct of activist investors.
Politan’s press release, which disclosed court proceedings sealed by a previous ruling, was deemed a violation by the U.S. Court for the Central District of California. The court stated that Politan’s disclosure gave it an unfair advantage in its proxy battle with Masimo, as the latter was unable to respond meaningfully due to the constraints of the sealing order.
Although the court ruled in favor of Masimo regarding the breach, it did not issue an injunction because the company failed to demonstrate significant economic damage from Politan’s actions. Furthermore, Politan had made corrective disclosures in response to the litigation.
MASI stock has gained 2% so far following the court ruling on Sept. 14. Year to date, Masimo’s shares have lost 1.9% against the industry’s growth of 9.8%. The S&P 500 Index has gained 18.1% in the said time frame.
Will MASI Gain From the Ruling?
The controversy stems from Politan’s broader agenda, which involves challenging the current leadership at Masimo. The investment firm has been vocal in its criticism of Masimo’s governance, particularly its alleged “egregious CEO benefits” and what Politan describes as “broken governance.”
In June 2024, Politan proposed two new board members, Darlene Solomon, former CTO of Agilent, and William Jellison, former CFO of Stryker, in an attempt to reshape Masimo’s leadership. According to Politan, these changes are necessary to safeguard the company’s future and maximize shareholder value.
However, the court’s contempt ruling has cast doubt on Politan’s ethical standing. Masimo’s management seized the opportunity to question the credibility and integrity of Politan, urging investors to vote against the firm’s nominees. The current board emphasized that Politan and its leadership, including Quentin Koffey, lack the necessary experience and qualifications to guide Masimo, further citing the court’s contempt ruling as evidence of Politan’s questionable conduct.
Importance of MASI’s Board Battle
The upcoming vote on Sept. 19 will determine the future of Masimo’s leadership. It could also result in Joe Kiani being ousted as CEO, a position he has held since the company’s inception. The court ruling adds a layer of complexity to the voting process, as shareholders must now weigh the legal and ethical implications of supporting Politan's candidates. If Politan succeeds, it could lead to a significant shift in Masimo’s strategic direction. A victory for MASI’s current board would maintain the status quo, albeit with renewed questions about governance and accountability. This ruling, therefore, plays a critical role in shaping the company’s future leadership and governance structure.
Masimo Corporation Price
Masimo Corporation price | Masimo Corporation Quote
MASI’s Zacks Rank & Other Key Picks
Currently, Masimosports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. DVA, Baxter International Inc. BAX and Boston Scientific Corporation BSX.
DaVita, flaunting a Zacks Rank #1 at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%. Its shares have risen 56.1% compared with the industry’s 26.3% growth in the past year.
Baxter, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.
Baxter has gained 2.9% compared with the industry’s 19.5% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific’s shares have rallied 57.7% compared with the industry’s 19.5% growth in the past year.
Zacks Investment Research
The S&P 500 Index today is down by -0.04%, the Dow Jones Industrials Index is down by -0.18%, and the Nasdaq 100 Index is up by +0.07%.
Stocks today are little changed on uncertainty ahead of the FOMC’s decision on interest rates this afternoon. Today’s reports showed that US housing starts and building permits for August were better than expected, bolstering the prospects for a soft landing and supporting stocks.
The markets will look to the 2-day FOMC meeting that concludes this afternoon to see whether policymakers will decide that a -25 bp cut in the fed funds target range would be adequate for a US economy that has shown signs of losing momentum or whether they will decide on a larger -50 bp rate cut instead. Also, fresh quarterly projections in the form of the Fed’s “dot plot” will offer further insight into the path of interest rates and the economy. In addition, today’s post-meeting comments from Fed Chair Powell will be scrutinized regarding the Fed’s future policy intentions.
US MBA mortgage applications rose +14.2% in the week ended September 13, with the purchase mortgage sub-index rising +5.4% and the refinancing mortgage sub-index rising +24.2%. The average 30-year fixed rate mortgage fell -14 bp to a 2-year low of 6.15% from 6.29% in the prior week.
US Aug housing starts rose +9.6% m/m to a 4-month high of 1.356 million, stronger than expectations of 1.318 million. Aug building permits, a proxy for future construction, rose +4.9% m/m to a 5-month high of 1.475 million, stronger than expectations of 1.410 million.
Hawkish comments today from former St. Louis Fed President Bullard weighed on bonds and stocks when he said the Fed should cut interest rates by -25 bp today as the case for a -50 bp rate cut is "overblown."
The markets are discounting the chances at 100% for a -25 bp rate cut at the conclusion of today’s FOMC meeting and at 64% for a -50 bp rate cut at that meeting.
Overseas stock markets today are mixed. The Euro Stoxx 50 is down -0.36%. China's Shanghai Composite recovered from a 7-1/4 month low and closed up +0.49%. Japan's Nikkei Stock 225 closed up +0.49%.
Interest Rates
December 10-year T-notes (ZNZ24) today are down -11 ticks. The 10-year T-note yield is up +4.7 bp at 3.693%. Dec T-notes today are moderately lower on negative carryover from a slide in European government bonds to 1-week lows. T-notes also fell on today’s stronger-than-expected US Aug housing starts and building permits reports. In addition, rising inflation expectations are bearish for T-notes after the 10-year breakeven inflation rate today rose to a 2-week high of 2.133%. T-notes extended their losses after former St. Louis Fed President Bullard said the FOMC should cut interest rates by only -25 bp today.
European government bond yields today are moving higher. The 10-year German bund yield climbed to a 1-week high of 2.195% and is up +4.9 bp at 2.192%. The 10-year UK gilt yield rose to a 1-week high of 3.854% and is up +8.5 bp at 3.852%.
ECB Governing Council member Villeroy de Galhau said, "The ECB has cut interest rates twice and should continue to cut them," as victory over inflation is "within sight."
Swaps are discounting the chances of a -25 bp rate cut by the ECB at 32% for the October 17 meeting.
US Stock Movers
Super Micro Computer is up more than +2% after Needham & Co. initiated coverage on the stock with a recommendation of buy with a price target of $600.
VF Corp is up more than +3% after Barclays upgraded the stock to overweight from equal weight with a price target of $22.
Victoria’s Secret & Co is up more than +3% after Barclays upgraded the stock to equal weight from underweight.
GE Healthcare is up more than +2% after BTIG upgraded the stock to buy from neutral with a price target of $100.
United States Steel is up more than +1% after a US security panel granted Nippon Steel permission to refile its plans to purchase the company for $14.1 billion.
Extra Space Storage is up more than +1% after Jeffries upgraded the stock to buy from hold with a price target of $204.
ResMed is down more than -4% to lead losers in the S&P 500 after Wolfe Research downgraded the stock to underperform from peer perform with a price target of $180.
Cencora is down more than -2% after Bank of America Global Research downgraded the stock to neutral from buy.
DaVita is down more than -1% on signs of insider selling after an SEC filing showed CEO Rodriguez sold $9.86 million of shares on Monday.
Workday is down more than -1% to lead losers in the Nasdaq 100 after Needham & Co. cut their price target on the stock to $300 from $350.
Hilton Grand Vacations is down more than -2% after Goldman Sachs initiated coverage on the stock with a sell recommendation and a price target of $31.
Incyte Corp is down more than -1% after Truist Securities downgraded the stock to hold from buy.
Earnings Reports (9/18/2024)
Ennis Inc (EBF), General Mills Inc (GIS), Steelcase Inc (SCS).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policyhere.
The S&P 500 Index today is up by +0.05%, the Dow Jones Industrials Index is down by -0.11%, and the Nasdaq 100 Index is up by +0.11%.
Stocks today are slightly higher ahead of the FOMC’s decision on interest rates this afternoon. Today’s reports showed US housing starts and building permits for August were better than expected, bolstering the prospects for a soft landing and boosting stocks.
The markets will look to the 2-day FOMC meeting that concludes this afternoon to see whether policymakers will decide that a -25 bp cut in the fed funds target range would be adequate for a US economy that has shown signs of losing momentum or whether they will decide on a larger -50 bp rate cut instead. Also, fresh quarterly projections in the form of the Fed’s “dot plot” will offer further insight into the path of interest rates and the economy. In addition, today’s post-meeting comments from Fed Chair Powell will be scrutinized regarding the Fed’s future policy intentions.
US MBA mortgage applications rose +14.2% in the week ended September 13, with the purchase mortgage sub-index rising +5.4% and the refinancing mortgage sub-index rising +24.2%. The average 30-year fixed rate mortgage fell -14 bp to a 2-year low of 6.15% from 6.29% in the prior week.
US Aug housing starts rose +9.6% m/m to a 4-month high of 1.356 million, stronger than expectations of 1.318 million. Aug building permits, a proxy for future construction, rose +4.9% m/m to a 5-month high of 1.475 million, stronger than expectations of 1.410 million.
The markets are discounting the chances at 100% for a -25 bp rate cut at the conclusion of today’s FOMC meeting and at 66% for a -50 bp rate cut at that meeting.
Overseas stock markets today are mixed. The Euro Stoxx 50 is down -0.36%. China's Shanghai Composite recovered from a 7-1/4 month low and closed up +0.49%. Japan's Nikkei Stock 225 closed up +0.49%.
Interest Rates
December 10-year T-notes (ZNZ24) today are down -9 ticks. The 10-year T-note yield is up +3.8 bp at 3.683%. Dec T-notes today are moderately lower on negative carryover from a slide in European government bonds to 1-week lows. Also, position squaring and long liquidation are weighing on T-notes ahead of this afternoon’s decision by the FOMC on interest rates. T-notes extended their losses after US Aug housing starts and building permits rose more than expected.
European government bond yields today are moving higher. The 10-year German bund yield climbed to a 1-week high of 2.185% and is up +4.1 bp at 2.184%. The 10-year UK gilt yield rose to a 1-week high of 3.837% and is up +6.8 bp to 3.836%.
ECB Governing Council member Villeroy de Galhau said, "The ECB has cut interest rates twice and should continue to cut them," as victory over inflation is "within sight."
Swaps are discounting the chances of a -25 bp rate cut by the ECB at 32% for the October 17 meeting.
US Stock Movers
Super Micro Computer is up more than +4% to lead gainers in the S&P 500 and Nasdaq 100 after Needham & Co. initiated coverage on the stock with a recommendation of buy with a price target of $600.
Cruise line operators are climbing today, with Carnival and Norwegian Cruise Line Holdings up more than +2% and Royal Caribbean Cruises Ltd up more than +1%.
VF Corp is up more than +5% after Barclays upgraded the stock to overweight from equal weight with a price target of $22.
Victoria’s Secret & Co is up more than +5% after Barclays upgraded the stock to equal weight from underweight.
United States Steel is up more than +1% after a US security panel granted Nippon Steel permission to refile its plans to purchase the company for $14.1 billion.
GE Healthcare is up more than +1% after BTIG upgraded the stock to buy from neutral with a price target of $100.
ResMed is down more than -5% to lead losers in the S&P 500 after Wolfe Research downgraded the stock to underperform from peer perform with a price target of $180.
Cencora is down more than -2% after Bank of America Global Research downgraded the stock to neutral from buy.
Incyte Corp is down more than -2% after Truist Securities downgraded the stock to hold from buy.
DaVita is down more than -2% on signs of insider selling after an SEC filing showed CEO Rodriguez sold $9.86 million of shares on Monday.
Edwards Lifesciences is down nearly -1% after Jeffries downgraded the stock to hold from buy.
Hilton Grand Vacations is down more than -1% after Goldman Sachs initiated coverage on the stock with a sell recommendation and a price target of $31.
Earnings Reports (9/18/2024)
Ennis Inc (EBF), General Mills Inc (GIS), Steelcase Inc (SCS).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policyhere.
Boston Scientific Corporation BSX recently received the Food and Drug Administration’s (FDA) approval to expand the indication for current-generation INGEVITY+ Pacing Leads. Expanded indication for INGEVITY+ Pacing Leads means thin wires will be placed inside the heart that will be connected to an implantable device. It can be used to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single or dual-chamber pacemaker.
The latest FDA approval enhances Boston Scientific’s commitment to developing safe and effective pacing technologies by providing physicians with LBBA-specific tools and educational resources.
BSX’s Likely Stock Trend Following the News
Following the announcement, shares of Boston Scientific lost 1.2% to $82.52 yesterday. However, the company continues to gain a high level of synergies from its continuous development within the cardiology space. Accordingly, we expect market sentiment toward BSX stock to eventually gain investors' optimism over this development.
Importance of BSX’s Expanded indication for INGEVITY+ Pacing Leads
Pacing of the LBBA is an alternative to traditional right ventricular pacing for the treatment of symptomatic bradycardia — a condition in which the heart beats too slowly. This pacing approach uses the heart's natural electrical system to place a lead in the LBBA of the heart's conduction system. This technique is expected to promote greater ventricular synchrony and reduce the long-term risk of heart failure associated with traditional right ventricular pacing.
Hence, the expanded indication for the INGEVITY+ Pacing Lead should enhance the implant experience for physicians and provide flexibility to determine the most appropriate pacing strategy based on individual patient characteristics.
Details of the FDA Approval
Clinical evidence submitted to the FDA to support the expanded indication includes data from approximately 400 patients from the INSIGHT-LBBA study. The study shows an analysis of the INGEVITY+ pacing leads that were previously implanted in the LBBA for anti-bradycardia pacing and were supplemented with bench testing and LATITUDE Programming System data.
Data demonstrated this lead to be safe and effective for LBBA pacing, allowing Boston Scientific to provide a new therapeutic option on a proven lead.
More on the News
The expanded indication followed the launch of the Boston Scientific CSP portfolio, including the OneLINK Splitter Cable, the INGEVITY+ Helix Locking Tool and site-selective pacing delivery catheters.
Industry Prospects Favor Boston Scientific
Per a Verified Market Research report, the pacing lead market was valued at $5.68 billion in 2024 and is projected to reach $7.8 billion by 2031, at a compound annual growth rate of 4.43% during the period. Key factors driving market growth include the increasing prevalence of cardiovascular diseases, technological advancements and the growing preference for minimally invasive operations.
Recent Development by BSX
On Tuesday, the company closed its acquisition of Silk Road Medical, Inc. With this, Boston Scientific should be able to strengthen its vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients (through the company’s significant commercial reach).
BSX’s Price Performance
In the past year, shares of BSX have risen 55.7% compared with the industry’s 20.3% growth.
BSX’s Zacks Rank and Other Key Picks
BSX currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are TransMedics Group TMDX, AxoGen AXGN and OrthoPediatrics KIDS. While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for TransMedics’ 2024 earnings per share (EPS) have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry’s 17.5% growth. TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%
Estimates for 2024 OrthoPediatrics’ loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 0.8% against the industry’s 18.1% growth. In the last reported quarter, KIDS delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
Zacks Investment Research
Charles River Laboratories International, Inc. CRL and CEBINA GmbH (Central European Biotech Incubator and Accelerator) have formed a strategic alliance under the DanubeNeuro acceleration program — an initiative focused on advancing groundbreaking academic research projects in the field of neurodegeneration, dementia and aging. The company’s extensive experience in neurotherapeutics will assist CEBINA in selecting and developing new product candidates.
Predicting CRL Stock’s Movement Following the Announcement
After the news release, shares of CRL rose 1.2% to $206.21 at the close of yesterday’s trading session. The latest development is expected to significantly boost the company’s Discovery Services business, a part of the Discovery and Safety Assessment (“DSA”) segment.
Recent advancements in genetics, pathology and biomarkers are speeding up the process of neuroscience drug discovery. Charles River is contributing to shaping neuroscience research, from providing deep translational expertise for preclinical models to novel drug discovery therapeutics, manufacturing and commercialization. We expect the market sentiment toward the stock to get a boost, driven by this development.
Impact of Charles River’s Participation in DanubeNeuro
With the trend of increasing lifespan, age-related conditions such as neurodegenerative disorders are becoming major and growing unmet medical needs worldwide, carrying significant and growing public health and societal implications. Given the urgent need for novel strategies and approaches to tackle complex diseases like Alzheimer’s and Parkinson’s, it is crucial to speed up the process of turning innovative academic ideas into viable drug development programs.
Launched by CEBINA earlier this year, DanubeNeuro identifies and develops pioneering research projects with the potential to create advanced drugs, diagnostic methods, disease biomarkers and imaging techniques for neurodegenerative diseases. CEBINA’s comprehensive selection process covers the key aspects of drug discovery and early-phase product development.
Projects selected for acceleration within DanubeNeuro will benefit from CEBINA’s experience from other acceleration programs, as well as Charles River’s knowledge and extensive expertise in drug discovery and development in the central nervous system field. DanubeNeuro is supported by a dedicated fund, Danube BioVentures. Together, Charles River and CEBINA will enhance this program’s potential to accelerate innovation in neurodegeneration.
Industry Prospects Benefiting CRL
According to Allied Market Research, the global neurodegenerative drugs market is forecasted to witness a compound annual rate of 7.5% through 2031 from a valuation of $36.28 billion in 2021. The rising prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis and Alzheimer's disease is fueling the demand for neurogenerative drugs. The growth of the market is likely to be driven by the high potential in untapped, emerging markets due to the availability of improved healthcare infrastructure and rising chronic disease rates.
Charles River’s Recent Developments
Earlier this month, Charles River and Insightec formed a five-year strategic partnership to integrate focused ultrasound for drug discovery and preclinical development of therapeutics in neuroscience. The collaboration will provide Charles River’s clients with access to a comprehensive global service and technology platform. Insightec’s novel low-frequency ultrasound platform non-invasively disrupts the blood-brain barrier, enabling drugs to be delivered to targeted brain areas.
CRL Stock Price Performance
Over the past year, shares of the company have fallen 1.1% against the industry’s growth of 15.1%.
CRL’s Zacks Rank and Top MedTech Stocks
Charles River carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 55.6% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 177.7% in the past year compared with the industry’s growth of 18%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for Phibro Animal Health’s 2024 earnings per share have risen 0.7% in the past 30 days. Shares of the company have rallied 79% in the past year compared with the industry’s 20.6% growth. PAHC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.1%. In the last reported quarter, it delivered an earnings surprise of 20.6%.
Zacks Investment Research
Corrects source from Masimo to Glass Lewis
Sept 17 (Reuters) - Glass Lewis:
LEADING PROXY ADVISORY FIRM GLASS LEWIS REITERATES RECOMMENDATION THAT MASIMO SHAREHOLDERS VOTE FOR BOTH OF POLITAN’S INDEPENDENT DIRECTOR NOMINEES
Source text for Eikon: (Full Story)
Further company coverage: MASI.O
(Reuters.Briefs@thomsonreuters.com)
Keywords: (CORRECTED)
Phibro Animal Health Corporation’s PAHC sustained growth in the Animal Health business is backed by robust sales of vaccines and Medicated Feed Additives ("MFAs"). The company’s focus on advancing vaccine technologies, along with the new vaccine production unit, instills optimism. Strong sales growth outside the United States seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro’s operations.
In the past year, this Zacks Rank #2 (Buy) stock has rallied 71.5% compared with the industry’s 19.5% growth and the S&P 500 composite's 25.7% increase.
The renowned animal health and mineral nutrition company has a market capitalization of $872 million. PAHC has an earnings yield of 21% compared with the industry’s 14.1%. In the last reported quarter, Phibro delivered an earnings surprise of 20.59%.
Let’s delve deeper.
Key Upsides of Phibro
Animal Health Business Growth Continues: With the rise in scarcity of natural resources, demand for efficient production of animal food such as poultry, swine and cattle has increased. Phibro’s key animal health products, including MFAs and nutritional specialty products, help enhance animal nutrition. The company also manufactures vaccines, which protect animals from both viral and bacterial diseases.
During the fiscal fourth quarter, Phibro entered into a Purchase and Sale Agreement with Zoetis to acquire Zoetis’ MFA product portfolio, certain water-soluble products and related assets.
The Animal Health business witnessed 8% sales growth year over year in the fiscal fourth quarter. The upside was driven by a robust 14% increase in vaccine net sales, due to poultry product introduction in Latin America and a rise in domestic demand. Phibro reported MFAs and Other net sales growth of 12% due to strong demand in both domestic and international regions.
Potential in Emerging Markets: Phibro’s existing operations and established sales, marketing and distribution network in more than 80 countries provide it with ample scope to take advantage of global growth opportunities. Outside the United States, its global footprint extends to key high-growth regions, including Brazil and other countries in South America, Southeast Asia, Eastern Europe and Africa.
At the end of fiscal 2024, the company’s operations in countries outside the United States contributed approximately 42.5% to its total revenues.
Prospering Vaccine Business: Phibro is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies. The company also makes significant investments to expand vaccine manufacturing capacity at several locations.
The vaccine business witnessed a robust 21% improvement in fiscal 2024, driven by a strong uptake across various regions, especially in Latin America. It also benefited from growing domestic demand. The company launched new commercial vaccines and looks forward to bringing additional vaccines to the Americas.
Key Downside of Phibro
Macroeconomic Concerns: In the current scenario, Phibro’s business could be severely impacted by economic sanctions, bans and broader military conflicts resulting from the ongoing armed conflict between Russia and Ukraine. Due to such unfavorable general economic conditions, its profitability could decline and negatively affect its overall financial performance.
In the fiscal fourth quarter, Phibro’s operating profit declined 21% while the operating margin contracted.
Estimate Trend of Phibro
The Zacks Consensus Estimate for Phibro’s fiscal 2025 earnings per share (EPS) has moved 0.7% north to $1.44 in the past 30 days.
The consensus estimate for fiscal 2025 revenues is pegged at $1.19 billion. This indicates a 17.1% rise from the year-ago number.
Other Key Picks
Other top-ranked stocks in the broader medical space are TransMedix Group TMDX, Intuitive Surgical ISRG and Boston Scientific BSX.
TransMedix Group’s earnings are expected to surge 255.8% in 2024. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 156.5% in the past year compared with the industry’s 17.5% growth.
TMDX sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry’s 13.7%. Shares of the company have risen 64.8% compared with the industry’s 17.6% growth over the past year.
ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 17.1% for 2024 compared with the industry’s 15.7%. In the past year, shares of BSX have risen 57.6% compared with the industry’s 19.5% growth.
BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.